Drug Trial Radar · NCT05067140
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
164
Actual
Start
Sep 2, 2021
Primary completion
May 25, 2027
Study completion May 25, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human, Phase 1/2, open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of JSB462 (luxdegalutamide, previously ARV-766) administered as monotherapy and in combination with abiraterone in participants with metastatic prostate cancer. The study includes dose-escalation and cohort expansion components to determine the recommended Phase 2 dose and assess clinical activity.
Conditions
- Prostate Cancer Metastatic
Interventions
ARV-766Drug
Parts A and C: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment. Part B: 100mg or 300mg oral tablet(s) once daily in 28 day cycles.
AbirateroneDrug
Abiraterone is administered orally in combination with ARV-766, typically on an empty stomach with water, in accordance with prescribing information and standard clinical practice.
Corticosteroid (e.g., prednisone/prednisolone)Drug
Prednisone or prednisolone was administered in accordance with local prescribing information during treatment with abiraterone acetate.
Androgen Deprivation Therapy (ADT)Other
Ongoing androgen deprivation therapy, including luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or prior orchiectomy, is maintained per investigator choice or patient preference.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatmentTime frame: Up to 28 days
- Part C: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatmentTime frame: Up to 28 Days
- Parts A and C: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From first dose through approximately 30 days after last dose
- Parts A and C: Incidence of laboratory abnormalitiesTime frame: From first dose through approximately 30 days after last dose
- Part B: Prostate-Specific Antigen 30% Response Rate (PSA30)Time frame: 12 Weeks
- Part B: Prostate-Specific Antigen 50% Response Rate (PSA50)Time frame: 12 Weeks
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical
Duarte, California
University of California San Diego - Moores Cancer Center
La Jolla, California
Providence Saint Johns Health Ctr
Santa Monica, California
Yale Cancer Center
New Haven, Connecticut
Florida Cancer Specialists
Fort Myers, Florida
Chesapeake Urology Associates
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Roswell Park Cancer Institute
Buffalo, New York
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Univ of Pittsburgh Cancer Inst
Pittsburgh, Pennsylvania
Carolina Urologic Research Center
Myrtle Beach, South Carolina
SCRI Oncology Partners
Nashville, Tennessee
Urology San Antonio
San Antonio, Texas
University of Virginia Medical Center
Charlottesville, Virginia
Virginia Cancer Specialists
Fairfax, Virginia
University of Wisconsin Paul P Carbone Comp Cancer Center
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.